ArticleJournal of the American Society of Nephrology : JASN2012
Anti-LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomerulonephritis.
Article in Journal of the American Society of Nephrology : JASN, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 121 citations in OpenAlex.
- The Influence and Role of Microbial Factors in Autoimmune Kidney Diseases: A Systematic Review.Journal of immunology research · 2015Pooled it
- Autoantibodies Against Lysosome Associated Membrane Protein-2 (LAMP-2) in Pediatric Chronic Primary Systemic Vasculitis.Frontiers in immunology · 2020Trial
- Anti-LAMP-2 Antibody Seropositivity in Children with Primary Systemic Vasculitis Affecting Medium- and Large-Sized Vessels.International journal of molecular sciences · 2024Article
- Pathogenesis of anti-neutrophil cytoplasmic antibody-associated vasculitis.Rheumatology and immunology research · 2023Review
- The Association of Serum Anti-Lysosomal-Associated Membrane Protein-2 Antibody with Vasculitis Combined with Hypertension.International journal of hypertension · 2022Article
- Lysosome function in glomerular health and disease.Cell and tissue research · 2021Review
- [ANCA diagnostics in vasculitis].Zeitschrift fur Rheumatologie · 2020Article
- ANCA-associated vasculitis.Nature reviews. Disease primers · 2020Review
- Animal Models of ANCA Associated Vasculitis.Frontiers in immunology · 2020Review
- Update on ANCA-associated vasculitis: from biomarkers to therapy.Journal of nephrology · 2019Review
- The Diagnostic and Clinical Utility of Autoantibodies in Systemic Vasculitis.Antibodies (Basel, Switzerland) · 2019Review
- Recent advances in understanding of the pathogenesis of ANCA-associated vasculitis.F1000Research · 2018Review
- ANCA-Associated Vasculitis Pathogenesis: A Commentary.Current rheumatology reports · 2017Review
- ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients.Nature reviews. Rheumatology · 2016Review
- Updates in ANCA-associated vasculitis.European journal of rheumatology · 2016Review
- Current and novel biomarkers in anti-neutrophil cytoplasm-associated vasculitis.Clinical kidney journal · 2016Article
- A historical study of American patients with anti-neutrophil cytoplasmic antibody negative pauci-immune glomerulonephritis.Clinical rheumatology · 2016Article
- Overview of the Pathogenesis of ANCA-Associated Vasculitis.Kidney diseases (Basel, Switzerland) · 2016Review
- Circulating ADAM17 Level Reflects Disease Activity in Proteinase-3 ANCA-Associated Vasculitis.Journal of the American Society of Nephrology : JASN · 2015Article
- Neutrophil extracellular trap formation is associated with autophagy-related signalling in ANCA-associated vasculitis.Clinical and experimental immunology · 2015Article
Corrections and comments
- Commented on by
Authors and funding
16 authors at 2 institutions in 1 country.
Funding
Abstract
Lysosomal membrane protein 2 (LAMP-2) is a target of antineutrophil cytoplasmic autoantibodies (ANCA) in addition to the more commonly known targets proteinase 3 and myeloperoxidase. The prevalence of anti-LAMP-2 antibodies and their relationship to disease in ANCA glomerulonephritis are not well described. We measured anti-LAMP-2 reactivity in 680 sera samples (two academic centers) from patients with ANCA glomerulonephritis (n=329); those with ANCA-negative glomerulonephritis (n=104); those with fimbriated, gram-negative Escherichia coli urinary tract infection (n=104); disease controls (n=19); and healthy volunteers (n=124). With levels in healthy controls used to define a reference range, anti-LAMP-2 reactivity was present in 21% of ANCA sera from two of the centers; reactivity was present in 16% of the control group with urinary tract infection. Western blotting and immunofluorescence microscopy did not verify positivity. Titers of anti-myeloperoxidase and anti-proteinase 3 antibodies were 1500-fold and 10,000-fold higher than anti-LAMP-2 titers, respectively. There was no correlation between anti-LAMP-2 antibodies and disease activity. Furthermore, Wistar Kyoto rats injected with anti-LAMP-2 antibodies did not develop glomerulonephritis. In conclusion, antibodies that react with LAMP-2 may exist at very low titers in a minority of patients with ANCA disease. These data do not support a mechanistic relationship between anti-LAMP-2 antibodies and ANCA glomerulonephritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.